Navigation Links
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 9, 2012 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2012 and a business outlook for the remainder of 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ), ... and Chief Executive Officer, will preside over the NASDAQ ... first day of Breast Cancer Awareness Month. In his ... on the important benefits of Hologic,s 3D Mammography technology, ... clinically superior to traditional mammography. This is ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
(Date:10/1/2014)... 01, 2014 Two bicyclists began a ... across the country in an effort to raise funds ... The cyclists, a father-daughter team, plan to bike ... Blaine, Washington and finishing in Key West Florida. ... The Warriors®, a national nonprofit organization that assists post-9/11 ...
(Date:10/1/2014)... UP4 Probiotics will be donating a portion ... National Network to End Domestic Violence ( http://www.nnedv.org ) ... through nationwide polling that took place during August and ... , “We are proud to have been chosen by ... of UP4 Women’s Probiotics during the month of October,” ...
(Date:10/1/2014)... 2014 After a run of successful ... emerging filmmaker Jacqui Blue is continuing her mission to ... truth about natural birth. The documentary has received a ... world and has been an effective medium for starting ... highlighted in the film provide a wealth of information ...
(Date:10/1/2014)... Looking for holiday gift ideas? Éminence Organic ... gift giving easy this holiday season. Starting October 1st 2014, ... solve all shopping dilemmas. Choose from two luxury skin care ... the delicate eye area or to deliver whole body beauty. ... Rescue Duo Gift Set are formulated to suit all skin ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 The annual ... levels again in 2015, says a new forecast by ... most recent consumer price index (CPI) data through August, TSCL ... “That would make the sixth consecutive year of record low ... the COLA first became automatic in 1975,” he notes. , ...
Breaking Medicine News(10 mins):Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Research (AADR) has announced Irwin D. Mandel, AADR past president ... of the inaugural 2010 AADR Distinguished Mentoring Award. This award ... in Washington, DC, March 3, 2010. Mandel began ... up his part-time private practice in 1968 to devote himself ...
... could lead to new treatments, study suggests , FRIDAY, Feb. ... for cystic fibrosis, U.S. researchers have identified a defective signaling ... disease. , Cystic fibrosis causes thick, sticky mucus to build ... of the most common potentially lethal genetic diseases in children ...
... ... ... ... ...
... ... ... the release of the 2010 U.S. Ambulatory EHR Study, a strategic analysis of the U.S. ... (HITECH) component of the American Recovery and Reinvestment (ARRA) Act. ,As recently presented at the ...
... they closely matched the real personalities of the profile ... the notion that Internet users favor idealized virtual identities, ... networking sites such as Facebook create profiles that stick ... networks may be more interested in fostering real communication ...
... ... ... ... ...
Cached Medicine News:Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2Health News:Facebook Profiles Don't Stretch the Truth 2Health News:Facebook Profiles Don't Stretch the Truth 3Health News:Facebook Profiles Don't Stretch the Truth 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 2Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 3Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 5Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 6Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 7Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 8Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 9Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 10Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 11Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 12Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 13Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 14Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 15Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 16
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
... is indicated for use in the thoracolumbar spine ... or excised for the treatment of tumors, to ... neural tissues, and to restore the height of ... also indicated for treating fractures of the thoracic ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
Medicine Products: